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Background
The use of biologic factors in the management of Juve-
nile Idiopathic Arthritis (JIA) has changed dramatically
the course and outcome of the disease. They control the
disease symptoms and hinder the joint damage which
may provoke major functional limitations, thus affecting
the patients’ Health Related Quality of Life (HRQoL).
Aim
To evaluate changes in the HRQoL variables in patients
with JIA, under anti-TNF treatment.
Methods
49 patients with refractory to conventional therapy JIA,
aged 2-18 years, were studied. They were receiving
either Etanercept or Adalimumab for the first time or
they were switchers from one anti-TNF to the other one
(10/49). All patients were clinically and laboratory
assessed pre-treatment and thereafter every 6 months,
until the completion of 2 years. At the same time-
points, the following variables were collected: the Child-
hood Health Assessment Questionnaire (CHAQ) Dis-
ability Index (DI), the patient’s/parent’s global
assessment of pain and wellbeing (P/PVAS) and the
physician’s global assessment (MDVAS) through the
visual analogue scale (VAS).
Results
During anti-TNF treatment, all the above mentioned
core set variables P/PVAS showed a significant
improvement (p<0.05). Similarly, the improvement of
MDVAS was positively correlated with the improvement
of CHAQ DI (rsq=0.43), of VAS pain (rsq=0.66) and of
VAS wellbeing (rsq=0.64). No correlation between VAS
wellbeing and JIA duration was found. Pain was the
only independent factor related with a poor score of
wellbeing.
Conclusion
This study shows that all variables associated with
HRQoL in patients with JIA can be substantially
improved after 2 years of anti-TNF treatment.
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